MPT WWW
Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.

Commentary

Kerry Win: Bad Medicine For Health Care
Dr. Scott Gottlieb, Forbes, 10-22-04

Some experts believe that a Kerry administration, much like President Clinton before him, would be forced to govern as a moderate by a staunchly Republican Congress. Kerry's rhetoric, however, leads one to expect the opposite: Kerry may claim to be many things, but a Clintonian New Democrat is not one of them.

Dr. Gottlieb points out that if Kerry's campaign rhetoric, much of it targeted against the pharmaceutical companies and the FDA, holds true to form, he could use strategic appointments to the FDA and the Centers for Medicare and Medicaid Services (along with stringent new regulations at both agencies) to substantially impede new drug development and slash industry profits. Gottlieb warns his readers "[not to] underestimate the impact that activist leadership inside the FDA and Medicare program can have on the industry, its prospect for profits and innovations for producing new medical products that improve the public health."



Project FDA.
  
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org